Alternating Treatment Regimens in Clear Cell Renal Cell Cancer
To delay disease progression in patients with progressive metastatic clear cell renal cell carcinoma, Geert A. Cirkel, MD, of the University Medical Center Utrecht, the Netherlands, and colleagues compared alternating first-line treatment with pazopanib and everolimus with continuous pazopanib in the randomized ROPETAR trial. The rotating treatment did not result in improved outcomes, suggesting the first-line treatment with a vascular endothelial growth factor inhibitor remains the optimal approach in this patient population. The full study findings were reported in JAMA Oncology.
A total of 101 patients with clear cell renal cell carcinoma took part in this clinical trial. Approximately half received an 8-week rotating schedule of pazopanib and everolimus, and the other half received pazopanib monotherapy.
Median progression-free survival favored the pazopanib monotherapy group over the rotating treatment group (9.4 vs 7.4 months). In addition, adverse events such as mucositis, anorexia, and dizziness were reported more often with the rotating first-line treatment. No difference in quality of life between the therapies was noted.